M&A Deal Summary

DifGen Acquires KriGen

On December 11, 2023, DifGen acquired life science company KriGen

Acquisition Highlights
  • This is DifGen’s 2nd transaction in the Life Science sector.
  • This is DifGen’s 2nd transaction in the United States.
  • This is DifGen’s 1st transaction in North Carolina.

M&A Deal Summary
Date 2023-12-11
Target KriGen
Sector Life Science
Buyer(s) DifGen
Deal Type Add-on Acquisition

Target

KriGen

Lillington, North Carolina, United States
KriGen is a fully integrated sterile drug product manufacturer with the capability to manufacture a wide range of parenteral products including LVP bags (both Aseptic & Terminally Sterilized), PFS, Microspheres& complex Long Acting Injectables. KriGen is based in Lillington, North Carolina.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

DifGen

Princeton, New Jersey, United States
Category Company
Sector Life Science
DESCRIPTION

DifGen is a pharmaceutical company with a primary focus on developing complex high barrier to entry Generics and Specialty Pharmaceutical products that would help increase accessibility to high-quality medication thereby leading to the creation of next-generation healthy communities. DifGen is based in Princeton, New Jersey.

DEAL STATS #
Overall 2 of 2
Sector (Life Science) 2 of 2
Type (Add-on Acquisition) 1 of 1
State (North Carolina) 1 of 1
Country (United States) 2 of 2
Year (2023) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2023-04-24 Aveva

Miramar, Florida, United States

AVEVA is a transdermal drug delivery provider. The company provides pharmaceutical partners with fully integrated, controlled-release transdermal products that fulfill unmet market needs or supply high-quality, affordable brand equivalents. Aveva was founded in 1991 and is based in Miramar, Florida.

Buy -
Mergr

Product

Company

Legal